MARKET

VNDA

VNDA

Vanda Pharms
NASDAQ

Real-time Quotes | Nasdaq Last Sale

13.37
-0.17
-1.22%
Opening 15:57 10/16 EDT
OPEN
13.50
PREV CLOSE
13.53
HIGH
13.59
LOW
13.14
VOLUME
366.22K
TURNOVER
--
52 WEEK HIGH
33.44
52 WEEK LOW
11.83
MARKET CAP
712.01M
P/E (TTM)
25.79
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of VNDA and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 6 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

VNDA News

  • SHAREHOLDER ALERT: The Law Offices of Timothy L. Miles Announces that Vanda Pharmaceuticals Inc. (VNDA) Sued for Misleading Investors; Shareholders Urged to Contact the Firm
  • ACCESSWIRE.1d ago
  • Volatility 101: Should Vanda Pharmaceuticals (NASDAQ:VNDA) Shares Have Dropped 42%?
  • Simply Wall St..6d ago
  • Menlo (MNLO) Completes Enrollment in Phase II Pruritus Study
  • Zacks.09/25 23:18
  • Vanda Pharmaceuticals Applauds the EPA's Landmark Commitment to Eliminate Animal Testing and Urges the Food and Drug Administration to End Unnecessary and Scientifically Flawed Animal Toxicity Studies
  • PR Newswire.09/11 22:20

More

Industry

Biotechnology & Medical Research
+0.16%
Pharmaceuticals & Medical Research
+0.04%

Hot Stocks

Name
Price
%Change

About VNDA

Vanda Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to address unmet medical needs. Its product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051. It offers HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24). HETLIOZ is in clinical development for the treatment of Pediatric Non-24, Jet Lag Disorder and Smith-Magenis Syndrome. It offers Fanapt for the treatment of schizophrenia. Fanapt has potential utility in various other disorders. Tradipitant is a small molecule neurokinin-1 receptor (NK-1R) antagonist, which is in clinical development for the treatment of chronic pruritus in atopic dermatitis. Trichostatin A is a small molecule histone deacetylase (HDAC) inhibitor. AQW051 is a Phase II alpha-7 nicotinic acetylcholine receptor partial agonist. AQW051 is indicated for the treatment of central nervous system disorders.
More

Webull offers Vanda Pharmaceuticals Inc. (VNDA) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.